Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation

Objectives: To provide an overview of drug treatment, transplantation, and gene therapy for patients with primary immunodeficiencies. Source of data: Non-systematic review of the literature in the English language carried out at PubMed. Synthesis of data: The treatment of patients with primary immun...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Gesmar Rodrigues Silva Segundo (Autore), Antonio Condino-Neto (Autore)
Natura: Libro
Pubblicazione: Elsevier, 2021-03-01T00:00:00Z.
Soggetti:
Accesso online:Connect to this object online.
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cdb3cc9b2c714718a9fb6ac91e9cb89b
042 |a dc 
100 1 0 |a Gesmar Rodrigues Silva Segundo  |e author 
700 1 0 |a Antonio Condino-Neto  |e author 
245 0 0 |a Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation 
260 |b Elsevier,   |c 2021-03-01T00:00:00Z. 
500 |a 0021-7557 
500 |a 10.1016/j.jped.2020.10.005 
520 |a Objectives: To provide an overview of drug treatment, transplantation, and gene therapy for patients with primary immunodeficiencies. Source of data: Non-systematic review of the literature in the English language carried out at PubMed. Synthesis of data: The treatment of patients with primary immunodeficiencies aims to control their disease, especially the treatment and prevention of infections through antibiotic prophylaxis and/or immunoglobulin replacement therapy. In several diseases, it is possible to use specific medications for the affected pathway with control of the condition, especially in autoimmune or autoinflammatory processes associated with inborn immunity errors. In some diseases, treatment can be curative through hematopoietic stem cell transplantation (HSCT); more recently, gene therapy has opened new horizons through new technologies. Conclusions: Immunoglobulin replacement therapy remains the main therapeutic tool. Precision medicine with specific drugs for altered immune pathways is already a reality for several immune defects. Advances in the management of HSCT and gene therapy have expanded the capacity for curative treatments in patients with primary immunodeficiencies. 
546 |a EN 
690 |a Primary immunodeficiency diseases 
690 |a Immunoglobulin therapy 
690 |a Antibiotic therapy 
690 |a Hematopoietic stem cell transplantation 
690 |a Gene therapy 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Jornal de Pediatria, Vol 97, Iss , Pp S17-S23 (2021) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S0021755720302229 
787 0 |n https://doaj.org/toc/0021-7557 
856 4 1 |u https://doaj.org/article/cdb3cc9b2c714718a9fb6ac91e9cb89b  |z Connect to this object online.